Ipsen SA has shown itself to be a canny dealmaker over the past few years and its negotiating skills have been shown again with the sale of a priority review voucher (PRV) at well above market rate.
Ipsen Outpaces Market With Lucrative Priority Review Voucher Deal
The going rate to buy a voucher that speeds up a regulatory review in the US is about $100m but the France-headquartered firm has managed to get considerably more from an unnamed big pharma.
More from Rare Diseases
More from Scrip
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
Recent moves in the industry include C-suite changes at Cronos and Accuryn Medical, plus Dyne Therapeutics Acquires Chief Financial Officer From Editas Medicine.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.